The PubMed entry reports the TRIANGLE randomized controlled trial titled: Rituximab Maintenance Added to Ibrutinib-Containing Therapy in Younger, Untreated Patients With Mantle Cell Lymphoma. The article was published in Journal of Clinical Oncology (J Clin Oncol) and is indexed under PubMed PMID 42447409. Citation details in the entry indicate: J Clin Oncol. 2026 Sep 20;44(27):2582-2589. doi: 10.1200/JCO-26-00705. Epub 2026 Jul 14.
The trial is identified explicitly as a Randomized Controlled Trial in the PubMed record. A free full-text copy is available through PubMed Central (PMC), as indicated by the full-text link in the source entry.
The PubMed record lists a large, multinational author group led by Marco Ladetto and colleagues and identifies the corporate author as the European MCL Network. Affiliations span a broad range of European and international academic centers, including institutions in Italy, Germany, the Netherlands, Spain, Sweden, Poland, Denmark, Switzerland, Norway, the Czech Republic, Belgium, Israel, Portugal, Finland, and others. This distribution reflects a multicenter cooperative effort across academic hematology/oncology units.
From the title and PubMed metadata, the patient population for the TRIANGLE trial is specified as younger, untreated patients with mantle cell lymphoma (MCL). The intervention tested was the addition of rituximab maintenance to an ibrutinib-containing therapy backbone. The title implies that the study evaluated the effect of continuing rituximab as maintenance therapy after (or alongside) an ibrutinib-based regimen in the frontline setting for a younger MCL cohort.
No further participant-level or regimen-level details (for example, precise age cutoffs defining “younger,” induction chemotherapy or immunochemotherapy components, dosing, duration of ibrutinib, timing of maintenance rituximab, or consolidation strategies such as autologous stem-cell transplant) are contained within the excerpt of the PubMed record provided here.
The PubMed entry provides direct links to the full text, including an Atypon provider link and a free PMC link. The record labels the study as a Randomized Controlled Trial and supplies DOI and publication date metadata. Interested readers and clinicians should consult the full-text version (PMC) for the complete methods, statistical analysis plan, and full results.
The excerpt of the PubMed record supplied for this rewrite includes title, author list, affiliations, article type, journal citation, DOI, and links to full text, but it does not include the abstract or the trial’s Results and Conclusions sections. Specific items that were not reported in the provided source text include, but are not limited to:
Because these critical design and outcome details are not present in the supplied excerpt, no efficacy or safety conclusions can be drawn from the text provided here. Any clinical interpretation requires review of the full-text manuscript in PMC and the published article.
Mantle cell lymphoma is a B-cell non-Hodgkin lymphoma for which frontline approaches have historically included combination immunochemotherapy with anti-CD20 antibodies (for example, rituximab) often followed by consolidation in selected younger patients. Targeted agents such as ibrutinib, a Bruton's tyrosine kinase inhibitor, have activity in MCL and are used in relapsed/refractory disease and are being integrated into frontline regimens in clinical trials. The strategy examined in TRIANGLE—adding rituximab maintenance to an ibrutinib-containing frontline approach—addresses the clinical question of whether prolonged anti-CD20 maintenance improves outcomes when ibrutinib is part of initial therapy.
The PubMed record confirms the importance of this question by reporting the randomized trial and the multinational collaboration, but does not provide trial outcomes in the supplied text.
The TRIANGLE trial appears to provide randomized evidence relevant to frontline management of younger patients with MCL comparing regimens that include or exclude rituximab maintenance when ibrutinib is used. Given that essential trial results and safety data were not included in the excerpt available here, clinicians should consult the full-text article (PMC link provided in the PubMed entry) to review the methods, statistical findings, efficacy endpoints (such as progression-free survival or overall survival), safety outcomes, and authors’ conclusions before considering changes to practice.
If you would like, I can:
Please confirm whether you want me to fetch and summarize the complete published results from the PMC full text.